The potentially risky move is meant to boost a nationwide COVID-19 vaccination program that has gotten off to a slow start
Mortality is higher in younger patients with COVID-19 compared with younger patients with influenza.
The FDA is alerting clinical laboratory staff and health care providers regarding the risk of false negative results with any SARS-CoV-2 test if a mutation occurs in the part of the virus’ genome assessed by that test.
Intensive health surveillance of close contracts of patients with COVID-19 provided a rare opportunity to determine asymptomatic attack rates and SARS-CoV-2 transmission risk factors.
The next difficult task in combating the COVID-19 pandemic will be to effectively distribute the vaccine and convince sufficient numbers of individuals to be vaccinated in order for herd immunity to be successful.
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
One reason for the lack of antiviral therapies for COVID-19 is the paucity of knowledge about the β-Coronavirus-host cell interface, until now.
Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.